China Adrenal Disease Registry

NCT04890444 | Recruiting

• 1 other identifier: Ruijin-adrenal01
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.

Conditions

Cushing Syndrome; Aldosteronism; Hypoadrenalism; Congenital Adrenal Hyperplasia; Adrenal Adenoma; Adrenal Incidentaloma; Adrenal Carcinoma; Pheochromocytoma

Outcome Measures

Primary Outcomes (2)

• Percentage of adrenal diseases in China

  through study completion, an average of 1 year

• Number of participants with complication of adrenal diseases in China

  through study completion, an average of 1 year

Secondary Outcomes (10)

• concentration of aldosterone

  through study completion, an average of 1 year

• concentration of cortisol

  through study completion, an average of 1 year

• concentration of urine cortisol

  through study completion, an average of 1 year

• concentration of androstenedione

  through study completion, an average of 1 year

• concentration of adrenocorticotropic hormone

  through study completion, an average of 1 year

Eligibility Criteria

• Age: 16 Years - 75 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is an observational study. Participants enrolled in the study were diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma. No gender restriction, between 16 and 75 years old.

You may qualify if:

• Age ≥ 16 years old and ≤ 75 years
• Patients diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma, etc.
• Provide written informed consent
• Satisfactory compliance

You may not qualify if:

• Patients with significantly reduced life expectancy (less than 2 years)
• With Drug abuse
• With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Endocrinology

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Cushing Syndrome; Hyperaldosteronism; Adrenal Insufficiency; Adrenal Hyperplasia, Congenital; ACTH Syndrome, Ectopic; Adrenal incidentaloma; Adrenal Cortex Neoplasms; Pheochromocytoma

Condition Hierarchy (Ancestors)

Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Adrenogenital Syndrome; Disorders of Sex Development; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Steroid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases; Gonadal Disorders; Paraneoplastic Endocrine Syndromes; Paraneoplastic Syndromes; Neoplasms; Adrenal Gland Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Adrenal Cortex Diseases; Paraganglioma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue

Central Study Contacts

shouyue SUN, MD

CONTACT

18121263206; ssy10926@rjh.com.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Head of Endocrinology, Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: May 7, 2021
• First Posted: May 18, 2021
• Study Start: June 1, 2021
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: February 14, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)